Reports indicate this pricing will offer years of revenue boost for the company.
QUICK FACTS:
- Pharmaceutical giant Pfizer has set the price of its COVID-19 vaccine at $110 to $130 per dose.
- Pfizer Inc. announced Thursday that it will be selling the COVID vaccine in the U.S. market once the shots become commercial.
- The shots will likely be available in the market during the first quarter of next year.
- During the emergency use allowances for the COVID-19 pandemic, Pfizer and partner BioNTech SE, have been receiving $30.50 per vaccine dose from the U.S. government.
- The roughly quadrupled price increase for this vaccine is expected to prompt a substantial revenue boost for Pfizer for “years” to come.
THE FUTURE OF THE VACCINE:
- COVID-19 vaccines have been made available to citizens of the United States and many countries, at the expense of their governments.
- The allowance was made both for the special use of the vaccines and the no-cost availability due to the government’s declaration of a public-heal emergency.
- However, the United States is not expected to renew that declaration next year, and an official for the commercial market for the COVID-19 vaccines tests and treatments says that companies producing the products still expect that Americans will be able to receive assistance in obtaining the products.
BACKGROUND:
- In August of this year, American Faith reported on data indicating that the more vaccines you take, the more likely you will catch COVID more than once. The Journal of the American Medical Association (JAMA), a peer-reviewed medical journal, published a study from Iceland in August revealing that the likelihood of being reinfected with coronavirus increases as the number of COVID vaccines taken increases.
- The study also showed that those who received zero COVID vaccines were less likely to be reinfected. The fewer vaccines you take, the less likely you will be reinfected.
- The JAMA publication reads: “The probability of reinfection increased with time from the initial infection (odds ratio of 18 months vs 3 months, 1.56; 95% CI, 1.18-2.08) (Figure) and was higher among persons who had received 2 or more doses compared with 1 dose or less of vaccine (odds ratio, 1.42; 95% CI, 1.13-1.78).”
